InflammamiRs in focus: Delivery strategies and therapeutic approaches
The FASEB Journal · 15.03.2024 · 38 (5)
DOI: 10.1096/fj.202302028r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 05.03.2024. Verfasst von Yeliz Z Akkaya-Ulum und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. Hauptthemen laut MEDLINE: MicroRNAs. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Technical and Scientific Research Council of Turkey (TUBITAK), Hacettepe University, Scientific Research Projects Coordination Unit, Türkiye Bilimsel ve Teknolojik Araştirma Kurumu.
Abstract (Originalsprache)
microRNAs (miRNAs) are small non‐protein‐coding RNAs which are essential regulators of host genome expression at the post‐transcriptional level. There is evidence of dysregulated miRNA expression patterns in a wide variety of diseases, such as autoimmune and inflammatory conditions. These miRNAs have been termed “inflammamiRs.” When working with miRNAs, the method followed, the approach to treat or diagnosis, and the selected biological material are very crucial. Demonstration of the role of miRNAs in particular disease phenotypes facilitates their evaluation as potential and effective therapeutic tools. A growing number of reports suggest the significant utility of miRNAs and other small RNA drugs in clinical medicine. Most miRNAs seem promising therapeutic options, but some features associated with miRNA therapy like off‐target effect, effective dosage, or differential delivery methods, mainly caused by the short target's sequence, make miRNA therapies challenging. In this review, we aim to discuss some of the inflammamiRs in diseases associated with inflammatory pathways and the challenge of identifying the most potent therapeutic candidates and provide a perspective on achieving safe and targeted delivery of miRNA therapeutics. We also discuss the status of inflammamiRs in clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
ORCID-Profile: Yeliz Z Akkaya-Ulum, Basak Sen, Tayfun Hilmi Akbaba, Banu Balci-Peynircioglu
Förderung
- Technical and Scientific Research Council of Turkey (TUBITAK)
- Hacettepe University, Scientific Research Projects Coordination Unit
- Türkiye Bilimsel ve Teknolojik Araştirma Kurumu
- Hacettepe Üniversitesi
Zitieren
APA
Akkaya-Ulum, Y. Z., Sen, B., Akbaba, T. H., & Balci-Peynircioglu, B. (2024). InflammamiRs in focus: Delivery strategies and therapeutic approaches. The FASEB Journal, 38(5). https://doi.org/10.1096/fj.202302028r
Vancouver
Akkaya-Ulum YZ, Sen B, Akbaba TH, Balci-Peynircioglu B. InflammamiRs in focus: Delivery strategies and therapeutic approaches. The FASEB Journal. 2024;38(5). doi:10.1096/fj.202302028r
BibTeX
@article{AkkayaUlum2024,
author = {Akkaya-Ulum, Yeliz Z and Sen, Basak and Akbaba, Tayfun Hilmi and Balci-Peynircioglu, Banu},
title = {InflammamiRs in focus: Delivery strategies and therapeutic approaches},
journal = {The FASEB Journal},
year = {2024},
volume = {38},
number = {5},
doi = {10.1096/fj.202302028r}
}
EUVIMED